DNA

Flowers may be more ancient than dinosaurs – but scientists can’t agree on when they evolved

Retrieved on: 
Tuesday, April 9, 2024

Including more than 350,000 known species, they dominate the ecological system, shape food webs and play a vital role in oxygen production.

Key Points: 
  • Including more than 350,000 known species, they dominate the ecological system, shape food webs and play a vital role in oxygen production.
  • Plus, many of them are valuable commercial crops – think of roses, grains and tomatoes.
  • A step change in research is shaking up the way scientists think about plants: they are far more complex and more like us than you might imagine.
  • But not all scientists agree it is an angiosperm, due to the different definitions of flower organs.
  • This is the largest known amber-preserved fossil flower, measuring about 3cm across and about three times as large as most floral fossils, showing beautiful details of this ancient flower.

Jurassic or Cretaceous?

  • The timing of flowers’ evolution is still a matter of debate between scientists, but most scientists are in one of two camps: Jurassic or Cretaceous.
  • Analyses using molecular data (DNA or protein sequences) suggest flowers could be much older than the fossil record shows – a Jurassic (145 million years ago) or even Triassic origin (201 million years ago).

Deciphering the past by molecular data

  • One technique scientists use to determine the timing of evolutionary events is the “molecular clock”.
  • This concept originated from the understanding that genetic mutations tend to accumulate at a constant rate across both time and species.
  • To construct a molecular clock, researchers analyse gene segments that have been conserved throughout a species’ evolution.

Piecing the puzzle together

  • Scientists examine fossil plants and observe the gradual changes in structures such as leaves, flowers and seeds over time.
  • Comparing their anatomy allows researchers to identify similarities and differences between extinct and still-living species, or species in different clades.
  • Biological traits which appear similar may be a result of convergent evolution, indicating changes in characteristics for environmental adaptation, rather than genetic similarity.

Mathematical approach can also help

  • There is also a mathematical approach to estimating the age of angiosperms – for instance, using the Bayesian Brownian Bridge (BBB) method.
  • This statistical model is a scientific formula that uses the distribution of fossils through time to estimate the age of a group.
  • By using the BBB method, an international research team found that the origin of angiosperms supports a pre-Cretaceous hypothesis.


Ruolin Wu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024

Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Key Points: 


Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Bridgeport Scores Big with the Grand Opening of New Sportsbook

Retrieved on: 
Monday, March 25, 2024

The Fanatics Sportsbook serves as the Connecticut Lottery Corporation’s (CLC) exclusive sports betting partner for mobile and retail betting.

Key Points: 
  • The Fanatics Sportsbook serves as the Connecticut Lottery Corporation’s (CLC) exclusive sports betting partner for mobile and retail betting.
  • Opening on Monday, March 25, patrons can now enter the Fanatics Sportsbook at Total Mortgage Arena near the main parking garage entrance at the site of the former Limerick Pub.
  • Hours of operation will be 11:30 am - 10 pm seven days a week, including days when arena events occur.
  • Fanatics Sportsbook online customers in Connecticut have been enjoying earning up to 5% back in FanCash on every bet.

ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie

Retrieved on: 
Monday, March 25, 2024

Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).

Key Points: 
  • Patients will have been previously treated with at least two therapies, including the antibody-drug conjugate (ADC) sacituzumab govitecan (SG; Trodelvy).
  • The TOPOLOGY trial is run by Institut Curie (Paris and Saint Cloud, France), with principal investigator Prof. Francois-Clement Bidard .
  • PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC.
  • Institut Curie has 3 sites (Paris, Saint-Cloud and Orsay) with over 3,700 health professionals working on treatment, research and teaching ([email protected]) Information on this clinical trial is available at clinicaltrials.gov, NCT06162351.

Vishay Intertechnology’s EFI Warwick Factory Certified to IATF 16949:2016 for IGBR Product Family

Retrieved on: 
Monday, March 25, 2024

Based on ISO 9001:2015 — with additional automotive customer-specific requirements — IATF 16949:2016 is the global technical specification and quality management standard for the automotive industry.

Key Points: 
  • Based on ISO 9001:2015 — with additional automotive customer-specific requirements — IATF 16949:2016 is the global technical specification and quality management standard for the automotive industry.
  • With this certification, the quality management system at the EFI Warwick factory is now certified to ISO 9001:2015 for all products, and IATF 16949:2016 for IGBR resistors.
  • In addition, its environmental management system is certified to ISO 14001:2015 and ISO 45001:2018.
  • Serving customers worldwide, Vishay is The DNA of tech.® Vishay Intertechnology, Inc. is a Fortune 1,000 Company listed on the NYSE (VSH).

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Retrieved on: 
Friday, March 22, 2024

U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.

Key Points: 
  • U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary method of preparing cell free DNA.
  • This method describes a key aspect of tumor-informed MRD assays that detect circulating tumor DNA (ctDNA) through sequencing.
  • Specifically, the patented method relates to the manner in which a sample is sufficiently enriched with ctDNA that it can be detected, if present, with high sensitivity and specificity.
  • “The 2016 filing date of this patent—at the advent of MRD development—highlights Myriad’s foresight about the potential role of tumor-derived cell-free DNA in the expanding field of cancer diagnostics,” said Paul J. Diaz, President and CEO, Myriad Genetics.

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Retrieved on: 
Friday, March 22, 2024

BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.

Key Points: 
  • The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
  • This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February.
  • “Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, March 21, 2024

"The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.

Key Points: 
  • "The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.
  • “Muscular Dystrophy Association’s funding was fundamental for the discovery of HDACi in the treatment of Duchenne muscular dystrophy.
  • “We’re excited to celebrate this additional treatment option for people living with Duchenne muscular dystrophy.
  • My son is an example,” said Jessica Curran, MDA family member and mother of Conner who lives with Duchenne muscular dystrophy.

IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024

Retrieved on: 
Thursday, March 21, 2024

LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m.

Key Points: 
  • LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 10:00 a.m.
  • To participate in the call, interested parties may dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.
  • The call will be archived for replay until April 11, 2024, and can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International Toll) using replay access code 8601697.
  • An audio replay of the call will also be available here for 90 days.

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Retrieved on: 
Thursday, March 21, 2024

EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.

Key Points: 
  • EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.
  • By hindering DNA repair, PARP inhibitors cause tumor cell death, and they have been effective therapies for many ovarian, breast, prostate, and pancreatic cancers.
  • EIS-12656 inhibits the chromatin remodeling enzyme ALC1, which is critical to the DNA repair process associated with PARP activation.
  • EIS-12656 was developed by Eisbach to disrupt DNA-damage-dependent PARP activation at an early stage of the repair process.